Related Experiment Video

Updated: Jun 29, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

Disrupting the Rb-Raf-1 interaction: a potential therapeutic target for cancer

Rebecca K Davis1, Srikumar Chellappan

  • 1Drug Discovery Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA.

Drug News & Perspectives
|October 7, 2008
PubMed

Insights

The retinoblastoma protein (Rb) interaction with Raf-1 kinase is crucial in cancer progression. Disrupting this interaction with RRD-251 shows promise for inhibiting cancer cell proliferation and tumor growth.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Cell-cycle progression is frequently dysregulated in cancer, often involving the retinoblastoma tumor suppressor protein (Rb).
  • Cyclin-dependent kinases (CDKs) and their cyclin partners regulate Rb phosphorylation, a key step in cell-cycle control.
  • The interaction between Raf-1 kinase and Rb occurs early in the cell cycle, preceding cyclin-CDK binding.

Purpose of the Study:

  • To investigate the role of the Rb-Raf-1 interaction in cancer development.
  • To explore the potential of targeting the Rb-Raf-1 interaction as a therapeutic strategy.
  • To review small molecules, such as RRD-251, that disrupt this interaction.

Main Methods:

  • Analysis of Rb-Raf-1 binding in human lung cancer samples.
  • Evaluation of the impact of disrupting the Rb-Raf-1 interaction on cancer cell proliferation.
  • Assessment of the effects of Rb-Raf-1 disruption on angiogenesis and tumor growth in vivo.
  • Characterization of small molecule inhibitors, specifically RRD-251.

Main Results:

  • Increased binding of Raf-1 to Rb was observed in human lung cancer tissues.
  • Disruption of the Rb-Raf-1 interaction demonstrated potential to inhibit cancer cell proliferation.
  • Targeting this interaction may prevent angiogenesis and reduce tumor growth in vivo.
  • RRD-251 was identified as a specific disruptor of the Rb-Raf-1 interaction.

Conclusions:

  • The Rb-Raf-1 interaction is a significant contributor to cancer malignancy.
  • Targeting protein-protein interactions, like Rb-Raf-1, offers a promising alternative to traditional kinase inhibition for cancer therapy.
  • RRD-251 represents a potential therapeutic agent for various cancer types by disrupting the Rb-Raf-1 pathway.

More Related Videos

Bioluminescence Resonance Energy Transfer (BRET)-Based Assay for Measuring Interactions of CRAF with 14-3-3 Proteins in Live Cells06:44

Bioluminescence Resonance Energy Transfer (BRET)-Based Assay for Measuring Interactions of CRAF with 14-3-3 Proteins in Live Cells

Published on: March 1, 2024

Related Concept Videos

The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...